ERBB2 and breast carcinoma: The rate of WGD exhibited remarkable variation across breast cancer subtypes, affecting 50.0% of TNBC samples versus only 14.1% of HR + /HER2- tumors, 23.1% of HR + /HER2 + and 20.0% of HER2 + tumors (Fig. 2a).